A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with histologically documented, incurable, locally advanced or metastatic solid malignancy that has progressed or failed to respond to at least one prior regimen, and who are not candidates for regimens known to provide clinical benefit
Evaluable or measurable disease per RECIST
Life expectancy of greater than or equal to (\>/=) 12 weeks
Documented willingness to use an effective means of contraception (for both men and women) while participating in the study
You may not be if
Leptomeningeal disease as the only manifestation of the current malignancy
History of Type 1 or 2 diabetes mellitus requiring regular medication
Any condition requiring anticoagulants, such as warfarin, heparin, or thrombolytics
Malabsorption syndrome or other condition that would interfere with enteral absorption
Known untreated central nervous system (CNS) malignancies or treated brain metastases that are not radiographically stable for \>/=3 months
Active congestive heart failure or ventricular arrhythmia requiring medication
Uncontrolled ascites requiring weekly large-volume paracentesis for 3 consecutive weeks prior to enrollment
Active infection requiring intravenous (IV) antibiotics
Requirement for any daily supplemental oxygen
Uncontrolled hypomagnesemia or hypokalemia, defined as values below the lower limit of normal (LLN), or hypercalcemia above the upper limit of normal (ULN) for the institution despite adequate electrolyte supplementation or management
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
Known human immunodeficiency virus (HIV) infection
Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participant at high risk from treatment complications
Significant traumatic injury within 3 weeks before Day 1
Major surgical procedure within 4 weeks prior to initiation of study treatment
Treatment with chemotherapy, hormonal therapy (except gonadotropin releasing hormone \[GnRH\] agonists or antagonists for prostate cancer), immunotherapy, biologic therapy, or radiation therapy (except palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of study treatment
Palliative radiation to bony metastases within 2 weeks prior to initiation of study treatment
Need for chronic corticosteroid therapy for greater than (\>) 7 days
Clareo Health | A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
